Generic Medicine Info
Indications and Dosage
Active immunisation against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Haemophilus influenza type B
Child: ≥2 months to <3 years As primary immunisation: 3 doses of 0.5 mL each to be given at 2, 3 and 4 months via deep inj into the anterolateral muscles of the thigh or the deltoid muscles of the upper arm. Alternatively, 2 doses of 0.5 mL each to be given at least 2-month intervals. As booster immunisation: 0.5 mL at least 6 months after last dose but, before 18 (if 3 doses primary immunisation) or between 11-13 months of age (if 2 doses). Refer to literature as dosage may vary with brand and local guidelines.
Hypersensitivity. Moderate or severe acute febrile illness or acute infection. History of encephalopathy within 1 week of pertussis vaccine.
Special Precautions
Patient with family or personal history of convulsions, sudden infant death syndrome (SIDS); Guillain-Barre syndrome, mild acute illness, ≥40.5°C temperature, hypotonic-hyporesponsive episode or crying for ≥3 hours within 48 hours or seizures within 3 days of pertussis vaccine; progressive neurological disorder, immunosuppression, bleeding disorder (e.g. thrombocytopenia).
Adverse Reactions
Significant: Fever (≥38°C temperature), hypotonic-hyporesponsive episode, inconsolable crying, irritability, seizures, syncope, Guillain-Barre syndrome, brachial neuritis; apnoea (premature infants).
Gastrointestinal disorders: Nausea, vomiting, diarrhoea.
General disorders and administration site conditions: Fatigue, inj site reactions (e.g. tenderness, pain, oedema, erythema).
Metabolism and nutrition disorders: Appetite loss.
Nervous system disorders: Somnolence.
Psychiatric disorders: Restlessness.
Potentially Fatal: Hypersensitivity or anaphylaxis reactions.
Monitoring Parameters
Monitor for signs and symptoms of hypersensitivity for 30 minutes, syncope for 15 minutes, apnoea in premature infants for 2-3 days after vaccination.
Drug Interactions
Decrease effect with immunosuppressive agents (e.g. corticosteroids, antimetabolites). Increased febrile reactions with pneumococcal conjugate or measles-mumps-rubella-varicella (MMRV) vaccine.
Lab Interference
May interfere with urine antigen detection for Haemophilus influenzae type B infection for a week.
Description: DTP-HIB-HBV-POL vaccine, a combination of diphtheria and tetanus toxoids, acellular pertussis, Haemophilus influenzae type B conjugate, recombinant hepatitis B and inactivated poliovirus vaccines, promotes immunity against diphtheria, tetanus, pertussis, Haemophilus influenzae type B or hepatitis B infection and poliomyelitis.
Store between 2-8°C. Do not freeze. Protect from light.
Any unused portions should be disposed of in accordance with local requirements.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J07CA09 - diphtheria-haemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B ; Belongs to the class of combined bacterial and viral vaccines.
Anon. Diphtheria and Tetanus Toxoids, Acellular Pertussis, Hepatitis B (Recombinant), Poliovirus (Inactivated) and Haemophilus influenzae B Conjugate (Adsorbed) Vaccine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 19/07/2018.

Buckingham R (ed). Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, and Haemophilus Influenzae Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 19/07/2018.

Joint Formulary Committee. Diphtheria with Tetanus, Pertussis, Hepatitis B, Poliomyelitis and Haemophilus Influenzae Type B Vaccine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 19/07/2018.

Disclaimer: This information is independently developed by MIMS based on Vaccine, DTP-HIB-HBV-POL from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in